Comparative In Vitro Cellular Data Alone Are Insufficient to Predict Clinical Responses and Guide the Choice of BCR-ABL Inhibitor for Treating Imatinib-Resistant Chronic Myeloid Leukemia

被引：48

作者：

Laneuville, Pierre ^{[1
]}

DiLea, Clifford ^{[2
]}

Yin, Ophelia Q. P. ^{[2
]}

Woodman, Richard C. ^{[2
]}

Mestan, Juergen ^{[3
]}

Manley, Paul W. ^{[3
]}

机构：

[1] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

[2] Novartis Pharmaceut, E Hanover, NJ USA

[3] Novartis Pharma AG, Basel, Switzerland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 11期

关键词：

TYROSINE KINASE INHIBITOR; NILOTINIB; DASATINIB; AMN107;

D O I：

10.1200/JCO.2009.26.4945

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E169 / E171

页数：3

共 6 条

[1] Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia [J].

Dai, Guowei ;

Pfister, Marc ;

Blackwood-Chirchir, Anne ;

Roy, Amit .

JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (11) :1254-1269

[2] Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance [J].

Kantarjian, Hagop M. ;

Giles, Francis ;

Gattermann, Norbert ;

Bhalla, Kapil ;

Alimena, Giuliana ;

Palandri, Francesca ;

Ossenkoppele, Gert J. ;

Nicolini, Franck-Emmanuel ;

O'Brien, Stephen G. ;

Litzow, Mark ;

Bhatia, Ravi ;

Cervantes, Francisco ;

Haque, Ariful ;

Shou, Yaping ;

Resta, Debra J. ;

Weitzman, Aaron ;

Hochhaus, Andreas ;

le Coutre, Philipp .

BLOOD, 2007, 110 (10) :3540-3546

[3]

Müller MC, 2008, BLOOD, V112, P171

[4] In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants [J].

O'Hare, T ;

Walters, DK ;

Stoffregen, EP ;

Jia, TP ;

Manley, PW ;

Mestan, J ;

Cowan-Jacob, SW ;

Lee, FY ;

Heinrich, MC ;

Deininger, MWN ;

Druker, BJ .

CANCER RESEARCH, 2005, 65 (11) :4500-4505

[5] Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants [J].

Redaelli, Sara ;

Piazza, Rocco ;

Rostagno, Roberta ;

Magistroni, Vera ;

Perini, Pietro ;

Marega, Manuela ;

Gambacorti-Passerini, Carlo ;

Boschelli, Frank .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :469-471

[6] Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib [J].

Tanaka, C. ;

Yin, O. Q. P. ;

Sethuraman, V. ;

Smith, T. ;

Wang, X. ;

Grouss, K. ;

Kantarjian, H. ;

Giles, F. ;

Ottmann, O. G. ;

Galitz, L. ;

Schran, H. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (02) :197-203

← 1 →